Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice
Risk of SARS-CoV-2 Infection and Hospitalisation in Immunocompromised Children: A Population-Based Cohort Study in Italy and Norway
ENABLE project launches to evaluate enhancement of treatment of HIV in infants by adding monoclonal antibodies
Quality Assurance & Auditing Manager
How can we end TB in children if we can’t find it?
The impact of Penta’s Youth Trial Boards
DTG/3TC is non-inferior to DTG-based 3-drug ART in children with HIV: D3/Penta 21 week-96 results
Proactive vs. reactive COVID-19 screening in schools: Lessons from experimental protocols in France during the Delta and Omicron waves
International Women’s Day – Women in STEM
Empirical treatment against cytomegalovirus and tuberculosis in severe pneumonia in HIV-infected infants: a randomized controlled clinical trial
Sex matters: A Bayesian approach to analyzing sex differences in an African pediatric cohort
Prime-boost HIVIS DNA and MVA-CMDR regimen induces robust Env and Gag antibody responses in youth living with HIV
HIV-1 DNA dynamics with HIVIS DNA/MVA-CDMR vaccinations +/-TLR4 Agonist: the HVRRICANE trial
Pharmacokinetics of a Novel Dose Ratio of DTG/FTC/TAF for African Children with HIV (UNIVERSAL1)
Exclusion is a risk: rethinking how to protect pregnant individuals in research
SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance
